

Practitioner's Docket No. MPI01-020P1RNM**REMARKS**

In response to the Restriction Requirement mailed May 9, 2005, Applicants respectfully point out the prior Restriction Requirement and election as not having been vacated. In this response, Applicants have presumed the first Restriction Requirement was intended to have been vacated and the mailed requirement effective to the claims as filed. Clarification is requested.

Still further, Applicants respectfully point out that the present Restriction Requirement is now incomplete and does not comprise all of the pending claims 1-72. Clarification is requested.

In response to the present Restriction Requirement, Applicants respectfully traverse the requirement in particular with regard to Group IV, drawn to a method for identifying a compound capable of treating a metabolic disorder caused by aberrant 14273 polypeptide activity (Claims 24 and 29 as designated by the Examiner) and Group XIII, drawn to a method for identifying a compound that can modulate an adipocyte activity by assaying the compound to test if it modulates the expression of a 14273 polypeptide activity (Claim 49 as designated by the Examiner). In particular, Applicants submit search and examination of Groups IV and XIII would in no manner be an undue burden. In fact, it is believed that a search of each of the groups would be co-extensive. Reconsideration and rejoinder of Groups IV and XIII is respectfully requested.

Furthermore, Applicants submit each of claims 24, 25, 26, 27, 28, and 29 should have been designated as corresponding to Group IV, and each of Claims 49, 50, 51, and 52 should have been designated as corresponding to Group XIII. Reconsideration and rejoinder of each of these claims into one group is requested.

In an effort to be fully responsive, Applicants hereby elect Group IV. It is believed each of Claims 24, 25, 26, 27, 28, and 29 should be designated as corresponding to this Group as being elected.

(Page 2 of 3)

Practitioner's Docket No. MPI01-020P1RNM

This paper is being filed timely and it is believed no extensions of time are required. In the event any extensions of time or fees are necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.


Entry of the remarks made herein is respectfully requested.

9 June 2005

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

By



Kerri Pollard Schray
Registration No. 47,066
40 Landsdowne Street
Cambridge, MA 02139
Telephone - 617-551-3676
Facsimile - 617-551-8820

(Page 3 of 3)